We dream big by thinking small, at the cellular level, inventing ways to destroy cancer and advance humanity.

Reimagining cell therapy

Powered by our novel D-Domain technology and paired with our transformative ddCAR and ARC-SparX platforms, our unique approach to cell therapy aims to supercharge how the world treats cancer.

Our Technology

delivering results
with every cell of our being

From the very beginning, our team has been united to destroy cancer and challenge convention—while ensuring patients stay at the forefront.

Mission-critical collaboration

Every day, we are building a more purposeful, empathetic team ready to work together to spearhead change and transform the fight against cancer. Join us.

Culture & Careers

Latest News

FOSTER CITY, Calif., December 13, 2021 – – Arcellx, Inc., a privately held clinical-stage biopharmaceutical company, today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. The clinical results are being presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

GAITHERSBURG, Md., November 4, 2021 – – Arcellx, Inc., a privately held clinical-stage biopharmaceutical company, today announced the presentation of new Phase 1 clinical trial data of its CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. The presentation at the 63rd American Society of Hematology Annual Meeting and Exposition will include

GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced the release of updated clinical data from the first 12 evaluable patients treated in the ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma. CART-ddBCMA is the company’s autologous,

Contact Us

Stay at the forefront of our advancements
in the battle against cancer.

*Required field

By clicking SUBMIT, you agree to our Terms & Conditions and Privacy Policy, and to receive information from Arcellx, its affiliates, service providers, and co-promotion partners.